Education
About Us
Working with TipRanks
Follow Us
Tarsus Pharmaceuticals (TARS)
NASDAQ:TARS
RESEARCH TOOLSreports
TARS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$20.08 - $57.28
Previous CloseN/A
Volume127.14K
Average Volume (3M)566.79K
Market Cap
$1.71B
Enterprise Value$1.02B
Total Cash (Recent Filing)$57.95M
Total Debt (Recent Filing)$164.00K
Price to Earnings (P/E)―
Beta0.94
Next Earnings
May 13, 2025EPS Estimate
-0.79Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.10
Shares Outstanding38,377,180
10 Day Avg. Volume756,467
30 Day Avg. Volume566,791
Standard Deviation0.19
R-Squared0.06
Alpha0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)12.89
Price to Cash Flow (P/CF)-48.30
P/FCF Ratio0.00
Enterprise Value/Market Cap0.60
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit64.20
Enterprise Value/Ebitda-8.04
Forecast
1Y Price Target
$69.29Price Target Upside55.78% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
---
Tarsus Pharmaceuticals News
---
Bulls Say, Bears Say
Bulls Say
EarningsTarsus Pharmaceuticals reported strong earnings with significant growth, beating consensus estimates for the fifth consecutive quarter.
Market PenetrationThe increase in Xdemvy prescriptions and surpassing the initial target prescriber base indicates robust demand and market penetration.
Bears Say
Spending ConcernsInvestors are concerned about cautious guidance on XDEMVY bottle volume and increased spending on marketing and R&D.
---
Ownership Overview
3.43% Insiders
16.66% Mutual Funds
3.28% Other Institutional Investors
62.95% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
TARS FAQ
What was Tarsus Pharmaceuticals’s price range in the past 12 months?
Tarsus Pharmaceuticals lowest stock price was $20.08 and its highest was $57.28 in the past 12 months.
What is Tarsus Pharmaceuticals’s market cap?
Tarsus Pharmaceuticals’s market cap is $1.71B.
When is Tarsus Pharmaceuticals’s upcoming earnings report date?
Tarsus Pharmaceuticals’s upcoming earnings report date is May 13, 2025 which is in 71 days.
How were Tarsus Pharmaceuticals’s earnings last quarter?
Tarsus Pharmaceuticals released its earnings results on Feb 25, 2025. The company reported -$0.6 earnings per share for the quarter, beating the consensus estimate of -$0.743 by $0.143.
Is Tarsus Pharmaceuticals overvalued?
According to Wall Street analysts Tarsus Pharmaceuticals’s price is currently Undervalued.
Does Tarsus Pharmaceuticals pay dividends?
Tarsus Pharmaceuticals does not currently pay dividends.
What is Tarsus Pharmaceuticals’s EPS estimate?
Tarsus Pharmaceuticals’s EPS estimate is -0.79.
How many shares outstanding does Tarsus Pharmaceuticals have?
Tarsus Pharmaceuticals has 38,377,180 shares outstanding.
What happened to Tarsus Pharmaceuticals’s price movement after its last earnings report?
Tarsus Pharmaceuticals reported an EPS of -$0.6 in its last earnings report, beating expectations of -$0.743. Following the earnings report the stock price went down -9.332%.
Which hedge fund is a major shareholder of Tarsus Pharmaceuticals?
Currently, no hedge funds are holding shares in TARS
---
Tarsus Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$69.29 (55.78% Upside)
$69.29 (55.78% Upside)
Blogger Sentiment
Bullish
TARS Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 658.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 5.5%
Last 30 Days ▼ 7.9%
Last 30 Days ▼ 7.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
17.45%
12-Months-Change
Fundamentals
Return on Equity
-54.83%
Trailing 12-Months
Asset Growth
41.74%
Trailing 12-Months
Company Description
Tarsus Pharmaceuticals
Tarsus Pharmaceuticals Inc is a late clinical-stage biopharmaceutical company. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's lead candidate TP-03, is a novel drug that targets the Demodex mite nervous system to kill the mites.
---
TARS Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted a year of strong financial performance and strategic advancements in Tarsus' pipeline, particularly with the success of XDEMVY and preparations for future product launches. However, challenges such as increased operational costs and anticipated headwinds in early 2025 were noted.Read More>---
TARS Stock 12 Month Forecast
Average Price Target
$69.29
▲(55.78% Upside)
Technical Analysis
EyePoint Pharmaceuticals
―
Ocular Therapeutix
―
Rocket Pharmaceuticals
―
Verona Pharma
―
scPharmaceuticals
―
Best Analysts Covering TARS
1 Year
1 Year Success Rate
12/14 ratings generated profit
1 Year Average Return
+47.09%
reiterated a buy rating 7 days ago
Copying Balaji Prasad's trades and holding each position for 1 Year would result in 85.71% of your transactions generating a profit, with an average return of +47.09% per trade.
---